Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Adial refines Phase 3 plans for AD04 in Alcohol Use Disorder, focusing on genetic subgroups and leveraging Cytel's advanced trial design expertise.

Data-Driven, Adaptive Trial Design: Adial partnered with Cytel to apply advanced statistical analytics and simulation ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Enlicitide decanoate is an investigational oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...

Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...